Analytical Data
-
Gene name
CT47A1
- Application
-
Alternative Names
CT47A1;CT47.1;CT47A2;CT47.2;Cancer/testis antigen 47A
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q5JQC4
-
Expression Region
1-288aa
-
AA Sequence
MSATGDRHPT QGDQEAPVSQ EGAQAEAAGA GNQEGGDSGP DSSDVVPAAE VVGVAGPVEG LGEEEGEQAA GLAAVPRGGS AEEDSDIGPA TEEEEEEEGN EAANFDLAVV ARRYPASGIH FVLLDMVHSL LHRLSHNDHI LIENRQLSRL MVGPHAAARN LWGNLPPLLL PQRLGAGAAA RAGEGLGLIQ EAASVPEPAV PADLAEMARE PAEEAAEEKL SEEATEEPDA EEPATEEPTA QEATAPEEVT KSQPEKWDEE AQDAAGEEEK EQEKEKDAEN KVKNSKGT
-
Molecular Weight
30.1 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CT47A1 is a member of the CT-antigen family, which is primarily expressed in testicular germ cells but is also found in various types of tumors, making it a potential biomarker for cancer diagnosis and a target for immunotherapy. Research on CT47A1 has gained traction due to its restricted expression profile; it is typically undetectable in normal adult tissues, except for the testis, thus enhancing its attractiveness as a target for cancer immunotherapy. The upregulation of CT47A1 in numerous malignancies suggests a role in tumorigenesis and cell proliferation, warranting investigation into its function and mechanisms. Understanding the immunogenicity of CT47A1 could provide insights into designing vaccines or other therapeutic strategies aimed at eliciting an immune response against tumors expressing this antigen. Additionally, studies on CT47A1 may contribute to elucidating broader patterns of cancer antigen expression, aiding in developing novel diagnostic tools and targeted therapies. Overall, the investigation of CT47A1 represents a promising avenue in cancer research, bridging molecular biology, immunology, and therapeutic development.











